russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2020-3858russjcardiol-3858Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWХроническая сердечная недостаточность и сахарный диабет 2 типа: состояние проблемыChronic heart failure and type 2 diabetes: state of the problemhttps://orcid.org/0000-0003-2592-0906БагрийА. Э.BagriyA. E.

Доктор медицинских наук, профессор, зав. кафедрой внутренних болезней № 2

Донецк

klassiki@inbox.ruhttps://orcid.org/0000-0002-0063-3428СупрунЕ. В.SuprunYe. V.

Заведующий отделением эндокринологии

Донецк

 

suprun5555@yandex.ruhttps://orcid.org/0000-0001-8625-1406МихайличенкоЕ. С.MykhailichenkoI. S.

Ассистент кафедры внутренних болезней №2

Донецк

kardiologDNR@yandex.ruhttps://orcid.org/0000-0001-6866-037XГолодниковИ. А.GolodnikovI. A.

Ассистент кафедры внутренних болезней №2

Донецк

golodnikov5555@yandex.ruГОО ВПО Донецкий национальный медицинский университет им. М. ГорькогоУкраинаDonetsk National Medical UniversityUkraineДорожная клиническая больница станции ДонецкУкраинаRailway Clinical Hospital of Donetsk stationUkraine20200705202025438583858Copyright © Багрий А.Э., Супрун Е.В., Михайличенко Е.С., Голодников И.А., 20202020Багрий А.Э., Супрун Е.В., Михайличенко Е.С., Голодников И.А.Bagriy A.E., Suprun Y.V., Mykhailichenko I.S., Golodnikov I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/3858

Хроническая сердечная недостаточность (ХСН) и сахарный диабет 2 типа (СД2т) представляют собой важные мультидисциплинарные проблемы как по отдельности, так и, особенно, в сочетании. Вопросы взаимного влияния рассматриваемых состояний, а также современные подходы к выбору лекарственных режимов при их комбинации остаются недостаточно известными отечественному практикующему врачу. В статье обсуждаются вопросы эпидемиологии, патофизиологии и основные принципы лечебной стратегии у лиц с ХСН и СД2т.

Heart failure (HF) and type 2 diabetes (T2D) are important multidisciplinary problems both individually and, especially, in combination. The issues of combine effect, as well as modern approaches to the choice of medication remain insufficiently known to practitioners in Russia. The article discusses the epidemiology, pathophysiology and the basic principles of therapy for people with HF and T2D.

сахарный диабетхроническая сердечная недостаточностьгликемияпатофизиологиялечениеdiabetesheart failureglycemiapathophysiologytreatmentReferencesRosano G, Vitale C, Seferovic P. Heart Failure in Patients with Diabetes Mellitus. Card Fail Rev. 2017;3(1):52-5. doi:10.15420/cfr.2016:20:2.Rosano G, Vitale C, Seferovic P. Heart Failure in Patients with Diabetes Mellitus. Card Fail Rev. 2017;3(1):52-5. doi:10.15420/cfr.2016:20:2.Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of cardiology (ESC) and the European association for the study of diabetes (EASD). European heart journal. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486.Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of cardiology (ESC) and the European association for the study of diabetes (EASD). European heart journal. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486.Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140(7):e294-e324. doi:10.1161/CIR.0000000000000691.Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140(7):e294-e324. doi:10.1161/CIR.0000000000000691.Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalenceestimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabetes research and clinical practice. 2019;157:107843. doi:10.1016/j.diabres.2019.107843.Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalenceestimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabetes research and clinical practice. 2019;157:107843. doi:10.1016/j.diabres.2019.107843.Шестакова М.В., Викулова О.К., Железнякова А.В., и др. Эпидемиология сахарного диабета в Российской Федерации: что изменилось за последнее десятилетие. Терапевтический архив. 2019;91(10):4-13. doi:10.26442/00403660.2019.10.000364.Shestakova MV, Vikulova OK, Zheleznyakova AV, et al. Diabetes epidemiology in Russia: what has changed over the decade? Therapeutic Archive. 2019;91(10):4-13. (In Russ.) doi:10.26442/00403660.2019.10.000364.Дедов И.И., Шестакова М.В., Викулова О.К., и др. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г. Сахарный диабет. 2018;21(3):144-59. doi:10.14341/DM9686.Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in Russian Federation: prevalence,morbidity, mortality, parameters of glycaemic control and structure of hypoglycaemic therapy according to the Federal Diabetes Register, status 2017. Diabetes Mellitus. 2018;21(3):144-59. (In Russ.) doi:10.14341/DM9686.Обрезан А.Г., Куликов Н.В. Хроническая сердечная недостаточность и сахарный диабет: патогенез и возможности лечения. Кардиология. 2018;58(7):85-94. doi:10.18087/cardio.2018.7.10156.Obrezan AG, Kulikov NV. Chronic Heart Failure and Diabetes Mellitus: Pathogenesis and Possibilities of Treatment. Kardiologiia. 2018;58(7):85-94. (In Russ.) doi:10.18087/cardio.2018.7.10156.Юрьева М.Ю., Дворяшина И.В. Значение гипергликемии и вариабельности гликемии у пациентов с декомпенсацией хронической сердечной недостаточности в зависимости от выраженности нарушений углеводного обмена. Кардиология. 2017;57(4S):38-46. doi:10.18087/cardio.2403.Yuryeva MY, Dvoryashina IV. Prognostic value of glycemic variability in patients with decompensated chronic heart failure and diabetes mellitus. Kardiologiia. 2017;57(4S):38- 46. (In Russ.) doi:10.18087/cardio.2403.Kristensen SL, Mogensen MU, Jhund PS, et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017;135(8):724-35. doi:10.1161/CIRCULATIONAHA.116.024593.Kristensen SL, Mogensen MU, Jhund PS, et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017;135(8):724-35. doi:10.1161/CIRCULATIONAHA.116.024593.Damman K, Solomon SD, Pfeffer MA, et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM‐study programme. European journal of heart failure. 2016;18(12):1508-17. doi:10.1002/ejhf.609.Damman K, Solomon SD, Pfeffer MA, et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM‐study programme. European journal of heart failure. 2016;18(12):1508-17. doi:10.1002/ejhf.609.Yang P, Feng J, Peng Q, et al. Advanced Glycation End Products: Potential Mechanism and Therapeutic Target in Cardiovascular Complications under Diabetes. Oxidative Medicine and Cellular Longevity. 2019;2019:1-12. doi:10.1155/2019/9570616.Yang P, Feng J, Peng Q, et al. Advanced Glycation End Products: Potential Mechanism and Therapeutic Target in Cardiovascular Complications under Diabetes. Oxidative Medicine and Cellular Longevity. 2019;2019:1-12. doi:10.1155/2019/9570616.Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. American Journal of Cardiology. 1972;30(6):595-602. doi:10.1016/0002-9149(72)90595-4.Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. American Journal of Cardiology. 1972;30(6):595-602. doi:10.1016/0002-9149(72)90595-4.Lorenzo-Almorós A, Tuñón J, Orejas M, et al. Diagnostic approaches for diabetic cardiomyopathy. Cardiovascular diabetology. 2017;16(28):1-14. doi:10.1186/s12933-017-506-x.Lorenzo-Almorós A, Tuñón J, Orejas M, et al. Diagnostic approaches for diabetic cardiomyopathy. Cardiovascular diabetology. 2017;16(28):1-14. doi:10.1186/s12933-017-506-x.Zoungas S, Arima H, Gerstein HC et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. The lancet Diabetes & endocrinology. 2017;5(6):431-7. doi:10.1016/S2213-8587(17)30104-3.Zoungas S, Arima H, Gerstein HC et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. The lancet Diabetes & endocrinology. 2017;5(6):431-7. doi:10.1016/S2213-8587(17)30104-3.American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes — 2020. Diabetes Care. 2020;43(Suppl.1):S66-S76. doi:10.2337/dc20-S006.American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes — 2020. Diabetes Care. 2020;43(Suppl.1):S66-S76. doi:10.2337/dc20-S006.Connelly KA, Gilbert RE, Liu P. Treatment of diabetes in people with heart failure. Canadian journal of diabetes. 2018;42:S196-S200. doi:10.1016/j.jcjd.2017.10.026.Connelly KA, Gilbert RE, Liu P. Treatment of diabetes in people with heart failure. Canadian journal of diabetes. 2018;42:S196-S200. doi:10.1016/j.jcjd.2017.10.026.Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34 000 patients. Circulation: Heart Failure. 2013;6(3):395- 402. doi:10.1161/CIRCHEARTFAILURE.112.000162.Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34 000 patients. Circulation: Heart Failure. 2013;6(3):395- 402. doi:10.1161/CIRCHEARTFAILURE.112.000162.Fujita Y, Inagaki N. Metformin: new preparations and nonglycemic benefits. Current diabetes reports. 2017;17(1):5. doi:10.1007/s11892-017-0829-8.Fujita Y, Inagaki N. Metformin: new preparations and nonglycemic benefits. Current diabetes reports. 2017;17(1):5. doi:10.1007/s11892-017-0829-8.Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586-93. doi:10.1007/s00125-017-4336-x.Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586-93. doi:10.1007/s00125-017-4336-x.Rosenstock J, Kahn SE, Johansen OD, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. Jama. 2019;322(12):1155-66. doi:10.1001/jama.2019.13772.Rosenstock J, Kahn SE, Johansen OD, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. Jama. 2019;322(12):1155-66. doi:10.1001/jama.2019.13772.Li J, Tong Y, Zhang Y, et al. Effects on all-cause mortality and cardiovascular outcomes in patients with type 2 diabetes by comparing insulin with oral hypoglycemic agent therapy: a meta-analysis of randomized controlled trials. Clinical therapeutics. 2016;38(2):372-86. e6. doi:10.1016/j.clinthera.2015.12.006.Li J, Tong Y, Zhang Y, et al. Effects on all-cause mortality and cardiovascular outcomes in patients with type 2 diabetes by comparing insulin with oral hypoglycemic agent therapy: a meta-analysis of randomized controlled trials. Clinical therapeutics. 2016;38(2):372-86. e6. doi:10.1016/j.clinthera.2015.12.006.Seferović PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European journal of heart failure. 2018;20(5):853-72. doi:10.1002/ejhf.1170.Seferović PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European journal of heart failure. 2018;20(5):853-72. doi:10.1002/ejhf.1170.Pich C, Michalik L. The Janus face of rosiglitazone. Oncotarget. 2018;9(102)37614-5. doi:10.18632/oncotarget.26532.Pich C, Michalik L. The Janus face of rosiglitazone. Oncotarget. 2018;9(102)37614-5. doi:10.18632/oncotarget.26532.Scheen AJ. GLP-1 receptor agonists and heart failure in diabetes. Diabetes & metabolism. 2017;43(Suppl.1):2S13-2S19. doi:10.1016/S1262-3636(17)30068-X.Scheen AJ. GLP-1 receptor agonists and heart failure in diabetes. Diabetes & metabolism. 2017;43(Suppl.1):2S13-2S19. doi:10.1016/S1262-3636(17)30068-X.Jia X, Alam M, Ye Y, et al. GLP-1 receptor agonists and cardiovascular disease: a meta-analysis of recent cardiac outcome trials. Cardiovascular drugs and therapy. 2018;32(1):65-72. doi:10.1007/s10557-018-6773-2.Jia X, Alam M, Ye Y, et al. GLP-1 receptor agonists and cardiovascular disease: a meta-analysis of recent cardiac outcome trials. Cardiovascular drugs and therapy. 2018;32(1):65-72. doi:10.1007/s10557-018-6773-2.Schernthaner G, Cahn A, Raz I. Is the use of DPP-4 inhibitors associated with an increased risk for heart failure? Lessons from EXAMINE, SAVOR-TIMI 53, and TECOS. Diabetes care. 2016;39(Suppl.2):S210-S218. doi:10.2337/dcS15-3009.Schernthaner G, Cahn A, Raz I. Is the use of DPP-4 inhibitors associated with an increased risk for heart failure? Lessons from EXAMINE, SAVOR-TIMI 53, and TECOS. Diabetes care. 2016;39(Suppl.2):S210-S218. doi:10.2337/dcS15-3009.Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet. 2019;393(10166):31-9. doi:10.1016/S0140-6736(18)32590-X.Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet. 2019;393(10166):31-9. doi:10.1016/S0140-6736(18)32590-X.Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136(3):249- 59. doi:CIRCULATIONAHA.117.029190.Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136(3):249- 59. doi:CIRCULATIONAHA.117.029190.Мареев В.Ю., Фомин И.В., Агеев Ф.Т. и др. Клинические рекомендации ОССН-РКО-РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158. doi:10.18087/cardio.2475.Mareev VY, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158. (In Russ.) doi:10.18087/cardio.2475.Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European journal of heart failure. 2016;18(8):891-975. doi:10.1093/eurheartj/ehw128.Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European journal of heart failure. 2016;18(8):891-975. doi:10.1093/eurheartj/ehw128.Кобалава Ж.Д., Медовщиков В.В., Ешниязов Н.Б., и др. Современная парадигма патофизиологии, профилактики и лечения сердечной недостаточности при сахарном диабете 2 типа. Российский кардиологический журнал. 2019;(11):98-111. doi:10.15829/1560-4071-2019-11-98-111.Kobalava ZhD, Medovchshikov VV, Yeshniyazov NB, et al. The modern paradigm of pathophysiology, prevention and treatment of heart failure in type 2 diabetes mellitus. Russian Journal of Cardiology. 2019;(11):98-111. (In Russ.) doi:10.15829/1560-4071-2019-11-98-111.Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a posthoc analysis from the PARADIGM-HF trial. The lancet Diabetes & endocrinology. 2017;5(5):333-40. doi:10.1016/S2213-8587(17)30087-6.Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a posthoc analysis from the PARADIGM-HF trial. The lancet Diabetes & endocrinology. 2017;5(5):333-40. doi:10.1016/S2213-8587(17)30087-6.Seferović PM, Coats AJS, Ponikowski P, et al. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure. European Journal of Heart Failure. 2020;22(2):196-213. doi:10.1002/ejhf.1673.Seferović PM, Coats AJS, Ponikowski P, et al. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure. European Journal of Heart Failure. 2020;22(2):196-213. doi:10.1002/ejhf.1673.Tsujimoto T, Kajio H, Shapiro MF, et al. Risk of all-cause mortality in diabetic patients taking β-blockers. Mayo Clinic Proceedings. Elsevier. 2018;93(4):409-18. doi:10.1016/j.mayocp.2017.11.019.Tsujimoto T, Kajio H, Shapiro MF, et al. Risk of all-cause mortality in diabetic patients taking β-blockers. Mayo Clinic Proceedings. Elsevier. 2018;93(4):409-18. doi:10.1016/j.mayocp.2017.11.019.Komajda M, Tavazzi L, Francq BG, et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Eur J Heart Fail. 2015;17(12):1294-301. doi:10.1002/ejhf.347.Komajda M, Tavazzi L, Francq BG, et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Eur J Heart Fail. 2015;17(12):1294-301. doi:10.1002/ejhf.347.McMurray JJ, Krum H, Abraham WT, et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine. 2016;374(16):1521-32. doi:10.1056/NEJMoa1514859.McMurray JJ, Krum H, Abraham WT, et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine. 2016;374(16):1521-32. doi:10.1056/NEJMoa1514859.Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Сахарный диабет. 2019;22(S.1):1-121. doi:10.14341/DM221S1.Dedov II, Shestakova MV, Maiorov AYu, et al. Standards of specialized diabetes care. Diabetus mellitus. 2019;22(S.1):1-121. (In Russ.) doi:10.14341/DM221S1.Фофанова Т.В., Агеев Ф.Т., Смирнова М.Д., и др. Приверженность к терапии в амбулаторных условиях: возможность выявления и оценка эффективности терапии. Кардиология. 2017;57(7):35-42. doi:10.18087/cardio.2017.7.10004.Fofanova TV, Ageev FT, Smirnova MD, et al. Adherence to Therapy in the Outpatient Setting: the Ability to Identify and Assess the Effectiveness of Therapy. Kardiologiia. 2017;57(7):35- 42. (In Russ.) doi:10.18087/cardio.2017.7.10004.Llano A, McKay G. The treatment of type 2 diabetes in heart failure. Practical Diabetes. 2018;35(4):123-6. doi:10.1002/pdi.2178.Llano A, McKay G. The treatment of type 2 diabetes in heart failure. Practical Diabetes. 2018;35(4):123-6. doi:10.1002/pdi.2178.Kaplinsky E. DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. Drugs in Context. 2020;9:2019-11-3. doi:10.7573/dic.2019-11-3.Kaplinsky E. DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. Drugs in Context. 2020;9:2019-11-3. doi:10.7573/dic.2019-11-3.Cherney DZI., Odutayo A, Verma S. A big win for diabetic kidney disease: CREDENCE. Cell metabolism. 2019;29(5):1024-7. doi:10.1016/j.cmet.2019.04.011.Cherney DZI., Odutayo A, Verma S. A big win for diabetic kidney disease: CREDENCE. Cell metabolism. 2019;29(5):1024-7. doi:10.1016/j.cmet.2019.04.011.

The authors declare that there are no conflicts of interest present.